- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rxsight Inc (RXST)
Rxsight Inc stock price live, this page displays NASDAQ RXST stock exchange data. View the RXST premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Rxsight Inc real time stock price chart below.
What Is the Rxsight Inc Stock Price Today?
The Rxsight Inc stock price today is 8.50.
What Is the Stock Symbol for Rxsight Inc?
The stock symbol for Rxsight Inc is ""RXST.""
What Stock Exchange Does Rxsight Inc Trade On?
Rxsight Inc is listed and trades on the NASDAQ stock exchange.
Is Rxsight Inc a Good Stock to Buy?
Determining whether Rxsight Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RXST quote. (ISIN: US78349D1072)
What Is the Rxsight Inc Stock Price Today?
The Rxsight Inc stock price today is 8.50.
What Is the Stock Symbol for Rxsight Inc?
The stock symbol for Rxsight Inc is ""RXST.""
What Stock Exchange Does Rxsight Inc Trade On?
Rxsight Inc is listed and trades on the NASDAQ stock exchange.
Is Rxsight Inc a Good Stock to Buy?
Determining whether Rxsight Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RXST quote. (ISIN: US78349D1072)
NASDAQ
Currency in USD
Fair Value
An estimate of a Rxsight's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.37
8.82
52 wk Range
6.32
57.53
RXST Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RXST is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Rxsight's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.378.82
52 wk Range
6.3257.53
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RXST Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Rxsight's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
8.89
Upside
+4.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings downwards for the upcoming period
- Rxsight receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Rxsight receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Rxsight receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Rxsight receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Rxsight receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Rxsight Inc Company Profile
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Rxsight Inc Earnings Call Summary for Q2/2025
- RxSight reported Q2 2025 EPS of -$0.29, missing forecast by 52.63%; revenue at $33.6M, down 4% YoY
- Stock rose 3.18% post-earnings despite miss, reflecting investor optimism on long-term growth potential
- Company expanding global reach, focusing on innovation; maintains strong financial health score
- Full-year 2025 revenue guidance set at $120M-$130M; gross margins expected 72-74%
- Management confident in LAL platform potential despite slower H2 outlook due to softness in adoption
Last Updated: 08/08/2025, 11:04
Read Full TranscriptCompare RXST to Peers and Sector
Metrics to compare | RXST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRXSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.8x | −3.8x | −0.5x | |
PEG Ratio | −0.53 | −0.21 | 0.00 | |
Price/Book | 1.3x | 2.9x | 2.6x | |
Price / LTM Sales | 2.4x | 3.6x | 3.3x | |
Upside (Analyst Target) | 6.0% | 25.9% | 38.7% | |
Fair Value Upside | Unlock | −0.9% | 5.0% | Unlock |
Analyst Ratings
1 Buy
8 Hold
2 Sell
Ratings:
11 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 8.89
(+4.58% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.29 / -0.19
Revenue / Forecast
33.60M / 38.55M
People Also Watch
FAQ
What Stock Exchange Does Rxsight Trade On?
Rxsight is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Rxsight?
The stock symbol for Rxsight is "RXST."
What Is the Rxsight Market Cap?
As of today, Rxsight market cap is 346.56M.
What Is Rxsight's Earnings Per Share (TTM)?
The Rxsight EPS (TTM) is -0.80.
When Is the Next Rxsight Earnings Date?
Rxsight will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is RXST a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Rxsight Stock Split?
Rxsight has split 0 times.
How Many Employees Does Rxsight Have?
Rxsight has 498 employees.
What is the current trading status of Rxsight (RXST)?
As of 27 Aug 2025, Rxsight (RXST) is trading at a price of 8.50, with a previous close of 8.50. The stock has fluctuated within a day range of 8.37 to 8.82, while its 52-week range spans from 6.32 to 57.53.
What Is Rxsight (RXST) Price Target According to Analysts?
The average 12-month price target for Rxsight is USD8.88889, with a high estimate of USD11 and a low estimate of USD8. 1 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an +4.58% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.